TABLE OF CONTENTS
1 INTRODUCTION 23
1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.3 OVERVIEW OF ASIA-PACIFIC KNEE CARTILAGE REPAIR MARKET 23
1.4 CURRENCY AND PRICING 25
1.5 LIMITATIONS 25
1.6 MARKETS COVERED 25
2 ASIA-PACIFIC KNEE CARTILAGE REPAIR MARKET: SEGMENTATION 27
2.1 MARKETS COVERED 27
2.2 GEOGRAPHICAL SCOPE 28
2.3 YEARS CONSIDERED FOR THE STUDY 28
2.4 DBMR TRIPOD DATA VALIDATION MODEL 29
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 32
2.6 MULTIVARIATE MODELLING 33
2.7 TREATMENT SEGMENT LIFELINE CURVE 33
2.8 DBMR MARKET POSITION GRID 34
2.9 MARKET APPLICATION COVERAGE GRID 36
2.10 SECONDARY SOURCES 37
3 EXECUTIVE SUMMARY 38
4 PREMIUM INSIGHTS 40
4.1 PESTEL ANALYSIS 41
4.2 PORTER'S FIVE FORCES MODEL 42
4.3 PATENT ANALYSIS 43
5 INDUSTRIAL INSIGHTS 46
6 EPIDEMIOLOGY 47
7 ASIA-PACIFIC KNEE CARTILAGE REPAIR MARKET, REGULATION 48
8 MARKET OVERVIEW 50
8.1 DRIVERS 52
8.1.1 INCREASE IN THE PREVALENCE OF KNEE DISORDERS 52
8.1.2 RISE IN THE NUMBER OF KNEE SURGERIES 52
8.1.3 GROWTH IN TECHNOLOGICAL ADVANCEMENTS 53
8.1.4 INCREASE IN DEMAND FOR MINIMALLY INVASIVE PROCEDURES 54
8.2 RESTRAINTS 55
8.2.1 HIGH COST OF THE ORTHOPEDIC KNEE IMPLANTS AND SURGERIES 55
8.2.2 RISE IN CONCERN REGARDING METAL SENSITIVITY IN PATIENTS WITH KNEE IMPLANTS 55
8.3 OPPORTUNITIES 56
8.3.1 RISE IN AWARENESS ABOUT KNEE TREATMENT 56
8.3.2 GROWING GERIATRIC POPULATION 57
8.3.3 HIGH PREVALENCE OF KNEE INJURIES 57
8.4 CHALLENGES 58
8.4.1 LACK OF SKILLED PROFESSIONALS 58
8.4.2 STRINGENT REGULATIONS 58
9 ASIA-PACIFIC KNEE CARTILAGE REPAIR MARKET, BY PRODUCT 59
9.1 OVERVIEW 60
9.2 CELL BASED 63
9.2.1 CHONDROCYTE TRANSPLANTATION 64
9.2.2 STEM CELL 64
9.2.3 GROWTH FACTORS 64
9.3 NON-CELL BASED 64
9.3.1 TISSUE SCAFFOLDS 65
9.3.2 CELL-FREE COMPOSITES 65
10 ASIA-PACIFIC KNEE CARTILAGE REPAIR MARKET, BY MODALITY 66
10.1 OVERVIEW 67
10.2 CHONDROCYTE IMPLANTATION 70
10.3 MICROFRACTURE 70
10.4 DRILLING 70
10.5 ABRASION ARTHROPLASTY 71
10.6 OSTEOCHONDRAL TRANSPLANTATION 71
10.7 OTHERS 72
11 ASIA-PACIFIC KNEE CARTILAGE REPAIR MARKET, BY CARTILAGE TYPE 73
11.1 OVERVIEW 74
11.2 HYALINE CARTILAGE 77
11.3 FIBROCARTILAGE 77
12 ASIA-PACIFIC KNEE CARTILAGE REPAIR MARKET, BY APPLICATION 78
12.1 OVERVIEW 79
12.2 OSTEOARTHRITIS 82
12.3 RHEUMATOID ARTHRITIS 82
12.4 FRACTURES 83
12.5 BONE TUMORS 83
12.6 OSTEONECROSIS 83
12.7 OTHERS 84
13 ASIA-PACIFIC KNEE CARTILAGE REPAIR MARKET, BY END USER 85
13.1 OVERVIEW 86
13.2 HOSPITALS 89
13.2.1 BY TYPE 89
13.2.1.1 PRIVATE 89
13.2.1.2 PUBLIC 89
13.2.2 BY SIZE 90
13.2.2.1 LARGE 90
13.2.2.2 MEDIUM 90
13.2.2.3 SMALL 90
13.3 AMBULATORY SURGICAL CENTERS 90
13.4 SPECIALTY CLINICS 91
13.5 RESEARCH AND ACADEMIC INSTITUTES 91
13.6 OTHERS 92
14 ASIA-PACIFIC KNEE CARTILAGE REPAIR MARKET, BY DISTRIBUTION CHANNEL 93
14.1 OVERVIEW 94
14.2 DIRECT SALES 97
14.3 THIRD PARTY DISTRIBUTORS 97
14.4 ONLINE SALES 97
14.5 OTHERS 98
15 ASIA-PACIFIC KNEE CARTILAGE REPAIR MARKET, BY COUNTRY 99
15.1 CHINA 104
15.2 JAPAN 110
15.3 INDIA 116
15.4 SOUTH KOREA 122
15.5 AUSTRALIA 128
15.6 THAILAND 134
15.7 MALAYSIA 140
15.8 SINGAPORE 146
15.9 INDONESIA 152
15.10 VIETNAM 158
15.11 PHILIPPINES 164
15.12 REST OF ASIA-PACIFIC 170
16 ASIA-PACIFIC KNEE CARTILAGE REPAIR MARKET, COMPANY LANDSCAPE 171
16.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 171
17 SWOT ANALYSIS 172
18 COMPANY PROFILES 173
18.1 SANOFI 173
18.1.1 COMPANY SNAPSHOT 173
18.1.2 REVENUE ANALYSIS 173
18.1.3 RODUCT PORTFOLIO 174
18.1.4 RECENT DEVELOPMENT 174
18.2 ZIMMER BIOMET 175
18.2.1 COMPANY SNAPSHOT 175
18.2.2 REVENUE ANALYSIS 175
18.2.3 PRODUCT PORTFOLIO 176
18.2.4 RECENT DEVELOPMENTS 176
18.3 SMITH & NEPHEW 177
18.3.1 COMPANY SNAPSHOT 177
18.3.2 REVENUE ANALYSIS 177
18.3.3 PRODUCT PORTFOLIO 178
18.3.4 RECENT DEVELOPMENTS 178
18.4 STRYKER 179
18.4.1 COMPANY SNAPSHOT 179
18.4.2 REVENUE ANALYSIS 179
18.4.3 PRODUCT PORTFOLIO 180
18.4.4 RECENT DEVELOPMENTS 180
18.5 MEDIPOST 181
18.5.1 COMPANY SNAPSHOT 181
18.5.2 REVENUE ANALYSIS 181
18.5.3 PRODUCT PORTFOLIO 182
18.5.4 RECENT DEVELOPMENT 182
18.6 ARTHREX, INC. 183
18.6.1 COMPANY SNAPSHOT 183
18.6.2 PRODUCT PORTFOLIO 183
18.6.3 RECENT DEVELOPMENT 183
18.7 ANIKA THERAPEUTICS, INC. 184
18.7.1 COMPANY SNAPSHOT 184
18.7.2 REVENUE ANALYSIS 184
18.7.3 PRODUCT PORTFOLIO 185
18.7.4 RECENT DEVELOPMENT 185
18.8 AUXEIN MEDICAL 186
18.8.1 COMPANY SNAPSHOT 186
18.8.2 PRODUCT PORTFOLIO 186
18.8.3 RECENT DEVELOPMENTS 186
18.9 B. BRAUN MELSUNGEN AG 187
18.9.1 COMPANY SNAPSHOT 187
18.9.2 PRODUCT PORTFOLIO 187
18.9.3 RECENT DEVELOPMENTS 187
18.10 BIOGEND THERAPEUTICS CO., LTD. 188
18.10.1 COMPANY SNAPSHOT 188
18.10.2 PRODUCT PORTFOLIO 188
18.10.3 RECENT DEVELOPMENTS 188
18.11 BIOTISSUE 189
18.11.1 COMPANY SNAPSHOT 189
18.11.2 PRODUCT PORTFOLIO 189
18.11.3 RECENT DEVELOPMENT 189
18.12 CONMED 190
18.12.1 COMPANY SNAPSHOT 190
18.12.2 REVENUE ANALYSIS 190
18.12.3 PRODUCT PORTFOLIO 191
18.12.4 RECENT DEVELOPMENT 191
18.13 CARTIHEAL, INC. (A SUBSIDIARY OF BIOVENTUS INC.) 192
18.13.1 COMPANY SNAPSHOT 192
18.13.2 REVENUE ANALYSIS 192
18.13.3 PRODUCT PORTFOLIO 193
18.13.4 RECENT DEVELOPMENT 193
18.14 DEPUY SYNTHES COMPANIES (A PART OF JHONSON & JHONSON MEDICAL DEVICES COMPANIES) 194
18.14.1 COMPANY SNAPSHOT 194
18.14.2 REVENUE ANALYSIS 194
18.14.3 PRODUCT PORTFOLIO 195
18.14.4 RECENT DEVELOPMENT 195
18.15 GEISTLICH PHARMA AG 196
18.15.1 COMPANY SNAPSHOT 196
18.15.2 PRODUCT PORTFOLIO 196
18.15.3 RECENT DEVELOPMENTS 196
18.16 MEDACTA INTERNATIONAL 197
18.16.1 COMPANY SNAPSHOT 197
18.16.2 PRODUCT PORTFOLIO 197
18.16.3 RECENT DEVELOPMENT 197
18.17 REGENTIS BIOMATERIALS LTD. 198
18.17.1 COMPANY SNAPSHOT 198
18.17.2 PRODUCT PORTFOLIO 198
18.17.3 RECENT DEVELOPMENTS 198
18.18 REGROW BIOSCIENCES PVT LTD. 199
18.18.1 COMPANY SNAPSHOT 199
18.18.2 PRODUCT PORTFOLIO 199
18.18.3 RECENT DEVELOPMENTS 199
18.19 SARTORIUS CELLGENIX GMBH 200
18.19.1 COMPANY SNAPSHOT 200
18.19.2 PRODUCT PORTFOLIO 200
18.19.3 RECENT DEVELOPMENT 200
18.20 WALDEMAR LINK GMBH & CO. KG 201
18.20.1 COMPANY SNAPSHOT 201
18.20.2 PRODUCT PORTFOLIO 201
18.20.3 RECENT DEVELOPMENTS 201
19 QUESTIONNAIRE 202
20 RELATED REPORTS 206

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.